Autonomix Medical Inc. (NASDAQ:AMIX) shares are skyrocketing Tuesday afternoon after securing U.S. Patent No. 12,433,670. Titled “Systems and Methods for Treating Cancer and/or Augmenting Organ Function,” the newly issued grant expands protection for the company’s minimally invasive nerve-mapping and targeting platform.

• Autonomix Medical stock is among today’s top performers. What’s behind AMIX gains?

New IP Drives Sharp Rally

Investors are responding enthusiastically as the intellectual property protects catheter-based microsurgical tools capable of recording electrophysiological neural signals and delivering energy or therapeutic agents directly to tumor-associated nerves.

The patent claims cover therapeutic applications across pancreatic, prostate, breast, colorectal, liver, ovarian and bone cancers.

Management Highlights Strategic Value

The technology allows clinicians to map neural activity and modulate autonomic nervous system signaling to treat severe cancer-related pain while influencing tumor microenvironments.

CEO Brad Hauser emphasized the milestone, stating, “This patent represents another meaningful expansion of our intellectual property portfolio and further demonstrates the breadth of our proprietary technology platform”.

AMIX Shares Surge Tuesday Afternoon

AMIX Price Action: Autonomix Medical shares were up 386.58% at $17.76 at the time of publication on Tuesday, according to Benzinga Pro data.

Image: Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.